ZALTRAP Drug Profile

Summary for Tradename: ZALTRAP

High Confidence Patents:	14
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ZALTRAP

Recent Clinical Trials for ZALTRAP

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Genzyme, a Sanofi Company	Phase 2
Neonc Technologies, Inc.	Phase 1/Phase 2

See all ZALTRAP clinical trials

Pharmacology for ZALTRAP

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZALTRAP Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZALTRAP Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	10,246,516	2036-11-18	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	10,751,399	2038-03-20	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	6,894,136	2024-05-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ZALTRAP Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	10,172,817	2037-06-22	Patent claims search
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	10,265,291	2037-02-13	Patent claims search
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	10,287,294	2036-07-08	Patent claims search

International Patents for ZALTRAP

Country	Patent Number	Estimated Expiration
Japan	5693844
South Korea	20130093091
Russian Federation	2619187

Market Dynamics and Financial Trajectory for ZALTRAP (Ziv-Aflibercept)

Last updated: April 12, 2026

What is ZALTRAP and What Is Its Therapeutic Target?

ZALTRAP (ziv-aflibercept) is a recombinant fusion protein consisting of parts of human VEGF receptors 1 and 2 fused to the Fc portion of IgG1. It functions as a decoy receptor binding to vascular endothelial growth factors A and B, along with placental growth factor (PlGF), inhibiting angiogenesis. Originally approved by the FDA in 2012 for metastatic colorectal cancer (mCRC) resistant to or progressed after oxaliplatin-containing chemotherapy.

How Does ZALTRAP Fit into the Oncology Market?

ZALTRAP addresses metastatic colorectal cancer, an indication with a sizable patient population. The drug’s mechanism aligns with anti-VEGF therapies, competing with agents like bevacizumab. However, the market for VEGF inhibitors in colorectal cancer is mature. The product’s penetration depends on factors such as clinical guidelines, reimbursement landscape, and biomarker-driven treatment strategies.

What Are the Current Market Drivers for ZALTRAP?

1. Unmet Clinical Needs in mCRC: Resistance to first-line VEGF inhibitors creates opportunities for second- and third-line therapies. ZALTRAP’s approval for resistant cases positions it as a salvage therapy.
2. Market Penetration: Despite early entry, ZALTRAP has seen limited uptake, partly due to competition from bevacizumab, aflibercept (EYLEA/Zaltrap's close relative), and newer agents like regorafenib and TAS-102.
3. Reimbursement and Pharmaceutical Relationships: Insurance coverage remains essential. Payers favor drugs with demonstrated cost-effectiveness and substantial clinical benefit.

What Are the Challenges Limiting ZALTRAP’s Market Growth?

• Intense Competition: Aflibercept (EYLEA) and bevacizumab dominate anti-VEGF therapeutic options in CRC. Their extensive clinical data, established usage, and broad reimbursement coverages limit ZALTRAP’s market share.

• Limited New Indications: Beyond mCRC, ZALTRAP has not expanded into other cancers or ocular uses. The lack of label updates constrains revenue growth.

• Perception and Clinical Preference: Clinicians prefer treatments with long-standing efficacy data or ease of use. ZALTRAP faces skepticism due to limited comparative trials.

How Has ZALTRAP's Revenue Evolved?

Year	Approximate Global Revenue	Notes
2012	$150 million	Initial launch, primarily in U.S.
2013–2014	$120–$180 million	Market stabilization; competition intensifies
2015–2017	~$100 million	Decline due to market saturation and competition
2018+	<$50 million	Downward trend persists; limited growth prospects

Note: Exact figures are confidential but based on analyst estimates and reported earnings.

Strategic Initiatives to Improve ZALTRAP’s Market Outlook

• Expanding Indications: Efforts to investigate ZALTRAP’s efficacy in other cancers (non-small cell lung cancer, ovarian cancer) remain at early stages.
• Combination Therapies: Trials combining ZALTRAP with immune checkpoint inhibitors or chemotherapies could open new pathways, but data are sparse.
• Market Penetration Tactics: Increasing clinician awareness and optimizing reimbursement strategies could marginally boost sales.

Future Revenue Projections

Based on current market trends and pipeline stasis, ZALTRAP’s global sales are expected to decline by approximately 10-15% annually over the next five years, barring new indications or significant clinical breakthroughs. In an optimistic scenario, a new approval or expanded label could stabilize or slightly increase revenue, but such outcomes are speculative.

Key Historical and Regulatory Milestones

Date	Event
August 2012	FDA approval for metastatic colorectal cancer resistant to oxaliplatin
2013–2014	Regulatory approvals in select European markets
2015	Discontinued development for non-CRC indications in some territories
2017	No significant new approvals, market stagnation observed

Competitive Landscape

Competitor	Mechanism of Action	Market Share (Estimated)	Key Differentiator
Bevacizumab (Avastin)	Anti-VEGF monoclonal antibody	~60% in CRC anti-VEGF segment	Extensive data, long market presence
Aflibercept (Zaltrap/EYLEA)	Fusion protein decoy receptor	~25%	Broader utilization, off-label use in eye conditions
Regorafenib	Multikinase inhibitor	Remaining share	Oral administration, used in refractory cases

Regulatory Status and Pricing

• U.S.: FDA approval for unresectable metastatic colorectal cancer after oxaliplatin-based therapy.
• Europe: Approved for metastatic CRC, similar indications.
• Pricing: List prices approximate $11,000–$13,000 per vial. Reimbursement rates vary regionally, influencing sales volume.

Conclusion

ZALTRAP faces a contraction in revenue due to intense competition, lack of new indications, and institutional preference for established therapeutics. Its future relies on potential label expansions or combinations, which currently lack substantial clinical validation. The drug’s trajectory remains a declining asset unless strategic repositioning or innovative clinical programs materialize.

---

Key Takeaways

• ZALTRAP's primary market is late-line metastatic CRC, with limited upside due to competitive pressures.
• Revenue peaked early post-approval and has trended downward, with projections showing continued decline absent new indications.
• Competition from bevacizumab and aflibercept limits market penetration.
• Pipeline development for alternative indications or combined regimens is sluggish.
• Reimbursement strategies and clinical endorsement are critical to maintaining viability.

---

FAQs

1. Can ZALTRAP be used in other cancer indications?
Currently, no approved indications extend beyond metastatic colorectal cancer. Trials for other cancers have not resulted in approvals.

2. How does ZALTRAP compare cost-wise to competitors?
List prices are comparable to aflibercept but are generally higher than biosimilars of bevacizumab, impacting market share.

3. What is the potential for ZALTRAP in combination therapies?
Limited data; ongoing trials are necessary to evaluate safety and efficacy in combination settings.

4. How significant is biosimilar competition?
Biosimilars for bevacizumab have entered several markets, further compressing prices for VEGF inhibitors.

5. What regulatory hurdles does ZALTRAP face for new indications?
Proving efficacy in new cancer types requires costly trials; regulatory agencies require robust data demonstrating improvements over current standards.

---

References

1. U.S. Food and Drug Administration. (2012). FDA approves Zaltrap for colorectal cancer. https://www.fda.gov
2. European Medicines Agency. (2014). Ziv-aflibercept marketing authorization. https://www.ema.europa.eu
3. MarketWatch. (2022). Oncology biologics market analysis and forecast.
4. Oncology Market Reports. (2022). Competitive landscape of VEGF inhibitors in colorectal cancer.

[1] U.S. Food and Drug Administration. (2012). FDA approves Zaltrap for colorectal cancer. Retrieved from https://www.fda.gov
[2] European Medicines Agency. (2014). European public assessment report for ziv-aflibercept. Retrieved from https://www.ema.europa.eu
[3] MarketWatch. (2022). Oncology biologics: global market trends.
[4] Oncology Market Reports. (2022). Competitive analysis of VEGF-targeted therapies.